Hema Laboratories Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 3.60 M
as on 16-11-2024
- Company Age 35 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 7.28 Cr
as on 16-11-2024
About Hema Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.60 M.
The company has closed loans amounting to ₹7.28 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Malhar Shah and Abhilash Shah serve as directors at the Company.
- CIN/LLPIN
U24231GJ1989PTC011749
- Company No.
011749
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jan 1989
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surendra Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Hema Laboratories Pvt Ltd offer?
Hema Laboratories Pvt Ltd offers a wide range of products and services, including Allopathic Cough Syrup, Benadryl Cough Syrup.
Who are the key members and board of directors at Hema Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Malhar Shah  | Director | 10-Dec-2015 | Current |
| Abhilash Shah | Director | 09-Jan-1989 | Current |
Financial Performance of Hema Laboratories.
Hema Laboratories Pvt Ltd, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Hema Laboratories?
In 2023, Hema Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 20 Mar 2015 | ₹3.00 Cr | Satisfied |
Small Industries Development Bank Of India Creation Date: 22 Sep 2011 | ₹1.60 M | Satisfied |
Small Industries Development Bank Of India Creation Date: 01 Jun 2010 | ₹1.95 M | Satisfied |
How Many Employees Work at Hema Laboratories?
Hema Laboratories has a workforce of 77 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hema Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hema Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
